adopting a robust Quality culture, to sustain the competitive edge in the long term. The company has formed strategic partnerships with international organizations and research institutions to enhance its biosimilars development capabilities along the value chain. Additionally, collaboration with local companies in US, EU, Japan, MENA and LATAM has helped Lupin expand its commercial footprint and reach in global markets.
Adherence to global standards has been the Mantra at Lupin! Lupin ' s biosimilars are developed in compliance with international regulatory standards, including those set by the US FDA, EMA, WHO,
PMDA, and Indian regulatory bodies. Lupin ' s biosimilars meet stringent quality and safety requirements, facilitating smoother market entry and acceptance in regulated markets. The company has built a strong pipeline of biosimilars targeting various therapeutic areas including autoimmune diseases, oncology, and ophthalmology, among others. Key products like Etanercept( Nepexto ®/ Rymti), Filgrastim( Lupifil ®), Peg-Filgrastim( Lupifil- P ®), Ranibizumab( Ranieyes) have been gaining approval in multiple markets, showcasing Lupin ' s ability to develop and commercialize complex biosimilars.
BioTech
BIOVOICENEWS. COM 27